

Contents

Peface — V

List of contributing authors — XIII

Magdalena Wiśniewska, Michał Wiśniewski and Marzena A. Lewandowska

1 Personalized and targeted therapies — 1

- 1.1 Introduction — 1
- 1.1.1 Predictive biomarkers — 1
- 1.1.2 Diagnostic biomarker — 2
- 1.1.3 Monitoring biomarker — 3
- 1.1.4 Risk (screening) biomarkers — 3
- 1.1.5 Pharmacodynamic (response) biomarkers — 3
- 1.1.6 Safety biomarker — 3
- 1.2 EGFR mutations — 4
- 1.3 ALK gene rearrangements — 5
- 1.4 ROS1 rearrangements — 6
- 1.5 RET rearrangements — 6
- 1.6 NTRK gene fusions — 7
- 1.7 MET ex14 skipping mutations — 8
- 1.8 BRAF-targeted therapies — 8
- 1.9 KRAS, NRAS and BRAF wild type in colorectal cancer — 10
- 1.10 Overexpression of platelet-derived growth factor receptor β (PDGFRB) in dermatofibrosarcoma protuberans (DFSP) and giant cell fibroblastoma (GCF) — 11
- 1.11 KIT and PDGFRA mutations in gastrointestinal stromal tumors — 12
- 1.12 Estrogen receptor — 13
- 1.13 PIK3CA mutations — 13
- 1.14 BRCA mutations — 14
- 1.15 HER-2 overexpression — 14
- 1.16 PD-L1 (programmed cell death receptor ligand 1) — 17
- 1.17 dMMR/MSI status — 18
- References — 19

Krzysztof Koper, Sławomir Wileński and Agnieszka Koper

2 Advancements in cancer chemotherapy — 27

- 2.1 Introduction — 27
- 2.2 The role of chemotherapy in cancer treatment — 28
- 2.3 The biological basis of chemotherapy — 28
- 2.4 Classification of cytostatic drugs — 28
- 2.4.1 Alkylating drugs — 29

2.4.2	Antimethabolites —	31
2.4.3	Plant alkaloids and other natural products —	33
2.4.4	Platinum derivatives —	36
2.5	Cell cycle–nonspecific and cell cycle–specific anticancer drugs —	36
2.6	Route of administration of chemotherapy and forms of anticancer drugs —	37
2.6.1	Importance of liposomes in clinical practice on the example of doxorubicin —	41
2.6.2	Subcutaneous administration —	42
2.6.3	Intraperitoneal chemotherapy —	43
2.6.4	Intrathecal chemotherapy —	45
2.6.5	Transarterial chemoembolisation —	45
2.6.6	Electrochemotherapy —	46
2.6.7	Implants —	46
2.6.8	Gene therapy —	46
2.7	Conclusion —	47
	References —	47

Janusz Winiecki

3	Principles of radiation therapy —	51
3.7.1	Ionizing radiation interaction with a living matter —	51
3.7.2	Treatment planning and realization of radiotherapy —	61
	References —	79

Karolina Balik, Karolina Matulewicz, Paulina Modrakowska,
Jolanta Kowalska, Xavier Montane, Bartosz Tylkowski and Anna Bajek

4	Advanced cell culture techniques for cancer research —	81
4.1	Cell-to-cell interactions —	81
4.1.1	Immunotherapy and cancer research —	81
4.1.2	Cancer microenvironment —	82
4.2	Standard methods of cell-to-cell interactions studies —	83
4.3	Microfluidic devices —	84
4.3.1	Microfluidic 2D models —	84
4.3.2	Microfluidics 3D models —	85
4.4	Artificial organs—why do we need them? —	87
4.4.1	Cell culture analog (CCA) system —	88
4.4.2	Organoids system —	90
4.5	“Omic” techniques in biological research —	92
4.6	Metabolomics —	93
4.7	Techniques for metabolomics in 2D cell culture —	95
4.7.1	Experimental design at the level of 2D cell culture —	95

- 4.7.2 Experimental design at the level of 3D cell culture — 97
- 4.8 The direction of *in vitro* cancer research — 98
- References — 98

Adrianna Sobolewska, Aleksandra Dunisławska and Katarzyna Stadnicka

5 Natural substances in cancer—do they work? — 103

- 6.1 Introduction — 103
- 6.2 Microbiome and cancer — 103
- 6.2.1 Probiotics and synbiotics in immunotherapy — 105
- 6.3 Food ingredients and cancer — 116
- 6.3.1 Resveratrol — 119
- 6.3.2 Curcumin — 122
- 6.3.3 Quercetin — 125
- 6.4 Summary — 127
- References — 128

Anna Helmin-Basa, Lidia Gackowska, Sara Balcerowska, Marcelina Ornowka,
Natalia Naruszewicz and Małgorzata Wiese-Szadkowska

6 The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer — 137

- 6.1 Introduction — 137
- 6.2 Innate immune cells and the tumor microenvironment — 141
- 6.3 NK cell-based immunotherapy in treating cancers — 144
- 6.3.1 Novel strategies for restoring NK cell anti-tumoral activity — 144
- 6.3.2 Anti-checkpoint receptor monoclonal antibodies — 144
- 6.3.3 Other antibodies — 148
- 6.3.4 Agonist antibodies — 149
- 6.3.5 Modified antibody molecules — 149
- 6.3.6 Fusion proteins — 150
- 6.3.7 Immunomodulatory drugs — 150
- 6.3.8 Cytokines — 151
- 6.3.9 Adoptive transfer of NK cells — 151
- 6.3.10 NK cells and combination immunotherapy — 152
- 6.3.11 Oncolytic virus-based therapy — 153
- 6.4 Macrophages in cancer treatment — 153
- 6.4.1 Depleting TAMs — 154
- 6.4.2 Reprogramming TAMs — 155
- 6.5 DCs in cancer treatment — 156
- 6.5.1 *Ex vivo* generated DC vaccines — 156
- 6.5.2 Targeting antigen to DCs *in vivo* — 158
- 6.6 Conclusions — 159
- References — 159

Łukasz Kiraga, Paulina Kucharzewska, Damian Strzemecki, Tomasz P. Rygiel and Magdalena Król

7 Non-radioactive imaging strategies for *in vivo* immune cell tracking — 173

- 7.1 Introduction — **173**
- 7.2 X-ray computed tomography (CT) — **174**
 - 7.2.1 CT contrast agents — **174**
 - 7.2.2 CT-based immune cell tracking — **176**
- 7.3 Magnetic resonance imaging (MRI) — **178**
 - 7.3.1 Paramagnetic contrast agents (T1 – shortening) — **178**
 - 7.3.2 Superparamagnetic contrast agents (T2 – shortening) — **179**
 - 7.3.3 “Hot-spot” MRI — **180**
 - 7.3.4 Highly-shifted proton (HSP) MRI — **181**
 - 7.3.5 CEST MRI — **182**
 - 7.3.6 PARACEST MRI — **182**
- 7.4 Optical imaging — **183**
 - 7.4.1 Bioluminescence Imaging (BLI) — **183**
 - 7.4.2 Fluorescence imaging (FLI) — **184**
- 7.5 Summary — **186**
- References — **188**

Xavier Montané, Karolina Matulewicz, Karolina Balik, Paulina Modrakowska, Marcin Łuczak, Yaride Pérez Pacheco, Belen Reig Vano, Josep M. Montornés, Anna Bajek and Bartosz Tylkowski

8 Present trends in the encapsulation of anticancer drugs — 193

- 8.1 Introduction — **193**
- 8.2 Encapsulated anticancer drug delivery systems — **194**
 - 8.2.1 Inorganic NPs — **196**
 - 8.2.2 Dendrimers — **196**
 - 8.2.3 Biopolymeric NPs — **198**
 - 8.2.4 Polymeric micelles — **199**
 - 8.2.5 Liposomes — **200**
 - 8.2.6 Polymersomes — **200**
 - 8.2.7 CNTs — **201**
 - 8.2.8 QDs — **202**
- 8.3 Hybrid encapsulation systems — **203**
- 8.4 Overview — **204**
- 8.4 Conclusions — **204**
- References — **207**

Łukasz Kaźmierski and Małgorzata Maj

9 3D tumor model – a platform for anticancer drug development — 213

- 9.1 Need for 3D tumor model (personalized medicine and drug development) — **213**
- 9.1.1 3D printed tumor models — **214**
- 9.1.2 Need for new *in vitro* models — **214**
- 9.2 General understanding of 3D printing technology — **214**
- 9.2.1 FDM 3D printing — **215**
- 9.2.2 SLA and MSLA 3D printing — **220**
- 9.2.3 SLM and DMLS 3D printing — **221**
- 9.3 3D *in vitro* model — **221**
- 9.3.1 Classical 2D cell culture — **222**
- 9.3.2 Spheroid culture — **222**
- 9.3.3 Classical 2D versus 3D cell culture approach — **223**
- 9.3.4 Spheroid formation methods — **224**
- 9.4 Bioprinting — **228**
- 9.4.1 Bioprinter types — **228**
- 9.4.2 Bioprinter media (bioinks) — **231**
- 9.4.3 Workflow and software — **232**
- 9.4.4 Typical concerns in bio-printing — **234**
- References — **238**

Index — 241